If you've heard the phrase "stem cell banking" and wondered what it actually means — where stem cells come from, what they do, and whether storing them at birth is worth it — you're in the right place. Understanding stem cells doesn't require a biology degree. It requires a clear, honest explanation. This guide covers everything expecting parents in the US need to know: what stem cells are, where they come from, what conditions they can treat, and how cord blood banking works — including what to consider when choosing a provider.
What Are Stem Cells, and Why Do They Matter?
Stem cells are the body's master cells. Unlike most cells in your body — which have a fixed job, like carrying oxygen or firing nerve signals — stem cells are unspecialised. They have two defining abilities: they can copy themselves (self-renewal), and they can develop into many different cell types (differentiation).
Think of them as biological blank slates. When the body needs to repair damaged tissue, fight disease, or replenish blood cells destroyed by chemotherapy, stem cells are the raw material it draws on.
💡 There are over 80 diseases currently treatable with cord blood stem cells — including leukaemia, aplastic anaemia, sickle cell disease, and certain immune disorders. The list continues to grow as clinical research advances.
This versatility is what makes stem cells so significant in medicine. They sit at the foundation of regenerative medicine — the field focused on repairing or replacing damaged cells, tissues, and organs.
Where Do Stem Cells Come From?
This is the question most parents ask first — and the answer is more straightforward than you might expect. Stem cells come from several sources:
1. Cord Blood (Umbilical Cord Blood): When a baby is born, the blood remaining in the umbilical cord and placenta is rich in haematopoietic stem cells (HSCs) — the type that gives rise to all blood and immune cells. This blood is collected after birth, after the cord is cut, and poses no risk to mother or baby. It is the primary source used in cord blood banking.
Cord blood stem cells are particularly valuable because they are young, immunologically naive (less likely to trigger rejection), and easy to collect non-invasively at a moment that would otherwise be lost forever.
2. Cord Tissue (Wharton's Jelly): The tissue of the umbilical cord itself — specifically a gelatinous substance called Wharton's jelly — contains mesenchymal stem cells (MSCs). These are different from HSCs: rather than forming blood cells, MSCs can differentiate into bone, cartilage, fat, and muscle tissue. They also have significant immunomodulatory properties, meaning they can regulate immune responses — which is why MSC research is active in areas like cerebral palsy, autism, and inflammatory conditions.
3. Placental Tissue: The placenta is collected at the same moment as cord blood and cord tissue, and like them it would otherwise be discarded — making it another rich, non-invasively obtained source. What makes the placenta distinctive is that it contains multiple stem cell populations in one tissue: mesenchymal stem cells (MSCs) within the chorionic and amniotic membranes, additional haematopoietic stem cells (HSCs), and amniotic epithelial cells, which have their own regenerative and immunomodulatory characteristics being studied in research settings. Because of this diversity, placental tissue is increasingly banked alongside cord blood and cord tissue to maximise the range of cells preserved from a single birth, complementing rather than duplicating what the cord itself provides.
4. Bone Marrow: Bone marrow has been used as a source of HSCs since the 1950s. Bone marrow transplants involve harvesting stem cells from a donor's hipbone — a procedure that requires anaesthesia and carries some discomfort. Cord blood offers a non-invasive alternative with a higher likelihood of donor-recipient matching within families.
5. Peripheral Blood: HSCs can be mobilised from bone marrow into the bloodstream using growth factor drugs, then collected via a process called apheresis. This is used in adult stem cell donation programmes.
6. Embryonic Stem Cells: Embryonic stem cells are pluripotent — capable of forming virtually any cell type in the body. They come from embryos at the blastocyst stage, typically those created during IVF. Their use raises ethical questions that have led to significant regulatory variation across countries. Most current clinical banking focuses on cord blood and cord tissue rather than embryonic sources.
7. Induced Pluripotent Stem Cells (iPSCs): A more recent development: scientists can reprogram ordinary adult cells (like skin cells) to behave like embryonic stem cells. iPSCs are a major area of research but are not yet widely used in clinical treatment.
For expecting parents, the most relevant and immediately actionable source is cord blood — collected once, at birth, and never available again.
The Science Behind Stem Cell Treatment
Stem cell therapies work by replacing or repairing damaged or diseased cells. In haematopoietic stem cell transplants (HSCTs) — the most established form of stem cell therapy — a patient's diseased blood system is destroyed (usually with chemotherapy or radiation) and rebuilt using healthy donor or autologous (self) stem cells.
A 2014 study in Biology of Blood and Marrow Transplantation reviewed outcomes across thousands of cord blood transplants and found that cord blood units with higher cell counts correlated with significantly better engraftment outcomes — underlining why collection quality and storage method matter.
A 2021 review in Pediatrics International documented the expanding therapeutic landscape for cord blood, noting active clinical trials in conditions including cerebral palsy, autism spectrum disorder, type 1 diabetes, and hypoxic-ischaemic encephalopathy — conditions not traditionally associated with stem cell treatment.
Beyond established transplant medicine, the frontier of stem cell research is expanding rapidly. Mesenchymal stem cells from cord tissue are being studied for their anti-inflammatory and regenerative properties in a growing number of clinical trials. This is why families increasingly opt to bank both cord blood and cord tissue — to preserve access to two distinct stem cell populations with complementary therapeutic profiles.
Stem Cells and Specific Conditions: What the Research Shows
Because this guide links to several in-depth articles, here is a brief overview of the key conditions where cord blood stem cells have established or emerging evidence:
Cerebral Palsy
Cerebral palsy affects approximately 1 in 345 children in the US. It results from brain injury — often around the time of birth — and currently has no cure. Cord blood infusions are among the most studied experimental interventions. A 2017 randomised trial published in Stem Cells found that children with cerebral palsy who received autologous cord blood infusions showed significant improvements in motor function compared to controls, with the strongest gains seen in children who received higher cell doses. Research in this area continues to develop, with 2026 studies refining dosing protocols and identifying which patient profiles respond best.
Aplastic Anaemia
Aplastic anaemia is a rare but life-threatening condition in which the bone marrow fails to produce enough blood cells. Cord blood transplants are an established treatment option — particularly important when a matched sibling donor is unavailable. A 2025 study in NIH demonstrated that cord blood transplants achieved durable engraftment in paediatric aplastic anaemia patients with overall survival rates comparable to bone marrow transplants, while offering greater donor availability. Cord blood's immunological flexibility often allows for partial HLA mismatches that bone marrow transplants cannot tolerate as well.
Leukaemia and Lymphoma
These blood cancers are among the longest-established indications for haematopoietic stem cell transplant. Cord blood has been used in thousands of transplants for paediatric and adult leukaemia patients worldwide since the late 1980s.
Sickle Cell Disease and Thalassaemia
Both are inherited red blood cell disorders for which stem cell transplant — from a matched sibling's cord blood — offers the best chance of cure. Banking cord blood at the birth of a sibling is one of the most clinically motivated reasons families choose to store.
The 80 Diseases Treated by Cord Blood
While much of the research above is still emerging, cord blood already has a long, established track record in transplant medicine. The stem cells found in a single cord blood unit are currently used to treat more than 80 diseases — a list that spans blood cancers, inherited blood and immune disorders, and rare metabolic conditions. Many of these are life-threatening illnesses for which a stem cell transplant offers the best, and sometimes the only, chance of a cure. The full list is below.
| Cancers | |
| Acute Biphenotypic Leukemia | Juvenile Myelomonocytic Leukemia (JMML) |
| Acute Lymphoblastic Leukemia (ALL) | Medulloblastoma |
| Acute Myelogenous Leukemia (AML) | Multiple Myeloma |
| Acute Undifferentiated Leukemia | Neuroblastoma |
| Chronic Lymphocytic Leukemia (CLL) | Non-Hodgkin's Lymphoma |
| Chronic Myelogenous Leukemia (CML) | Plasma Cell Leukemia |
| Chronic Myelomonocytic Leukemia (CMML) | Retinoblastoma |
| Hodgkin's Lymphoma | Waldenstrom's Macroglobulinemia |
| Juvenile Chronic Myelogenous Leukemia (JCML) | |
| Blood Disorders | |
| Acute Myelofibrosis | Glanzmann Thrombasthenia |
| Agnogenic Myeloid Metaplasia (Myelofibrosis) | Myelodysplastic Syndrome (MDS) |
| Amyloidosis | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Congenital Amegakaryocytosis Thrombocytopenia | Polycythemia Vera |
| Aplastic Anemia | Pure Red Cell Aplasia |
| Beta Thalassemia Major | Refractory Anemia |
| Congenital Dyserythropoietic Anemia | Refractory Anemia with Excess Blasts |
| Diamond-Blackfan Anemia | Refractory Anemia with Excess Blasts in Transformation |
| Essential Thrombocythemia | Refractory Anemia with Ringed Sideroblasts |
| Fanconi Anemia | Sickle Cell Disease |
| Immune Disorders | |
| Ataxia-Telangiectasia | Lymphoproliferative Disorders |
| Bare Lymphocyte Syndrome | Myelokathexis |
| Cartilage-Hair Hypoplasia | Neutrophil Actin Deficiency |
| Chediak-Higashi Syndrome | Omenn Syndrome |
| Chronic Granulomatous Disease | Pearson's Syndrome |
| Common Variable Immunodeficiency | Reticular Dysgenesis |
| DiGeorge Syndrome | SCID which is X-linked |
| Erythropoietic Porphyria | SCID with absence of T & B Cells |
| Hemophagocytic Lymphohistiocytosis | SCID with absence of T Cells, Normal B Cells |
| Hermansky-Pudlak Syndrome | SCID with Adenosine Deaminase Deficiency (ADA-SCID) |
| Infantile Genetic Agranulocytosis (Kostmann Syndrome) | Shwachman-Diamond Syndrome |
| Leukocyte Adhesion Deficiency | Systemic Mastocytosis |
| Lymphoproliferative Disorder, X-linked | Wiskott-Aldrich Syndrome |
| Metabolic Disorders | |
| Adrenoleukodystrophy (ALD) | Niemann-Pick Disease |
| Hunter Syndrome (MPS-II) | Osteopetrosis |
| Hurler Syndrome (MPS-IH) | Pelizaeus-Merzbacher Disease |
| Krabbe Disease (Globoid Cell Leukodystrophy) | Sandhoff Disease |
| Lesch-Nyhan Syndrome | Sanfilippo Syndrome (MPS-III) |
| Maroteaux-Lamy Syndrome (MPS-VI) | Scheie Syndrome (MPS-IS) |
| Metachromatic Leukodystrophy | Sly Syndrome (MPS-VII) |
| Morquio Syndrome (MPS-IV) | Wolman Disease |
| Mucolipidosis II (I-cell Disease) | |
The Birth Window: Why Timing Is Everything
One topic that surprises many parents is just how time-sensitive cord blood collection is. The stem cells in umbilical cord blood are only collectable in the minutes immediately following birth. Once discarded, they are gone.
This connects to several pregnancy milestones that matter for cord blood banking:
-
The Mucus Plug and Labour Onset: The mucus plug seals the cervix during pregnancy, protecting the uterus from infection. Its discharge — sometimes called a "bloody show" — often signals that labour is approaching, though it can precede active labour by days or even weeks. Recognising this sign matters for banking families because it's an early cue to ensure your collection kit is ready and your hospital team is briefed.
-
Braxton Hicks vs Real Contractions: Knowing the difference between practice contractions and active labour is practically important for any family planning cord blood banking. Arriving at hospital too early — or too late — can affect the collection process. A clear understanding of labour signs helps families stay calm and prepared.
-
Twin Pregnancies: Twin pregnancies introduce additional complexity for cord blood banking. Fraternal twins (dizygotic) each have their own placenta and cord blood — meaning two separate collections are possible. Identical twins (monozygotic) may share a placenta, which affects collection logistics. Understanding the genetics also matters: fraternal twins are no more genetically similar than regular siblings, while identical twins share nearly 100% of their DNA.
How Cord Blood Banking Works in Practice
The process is simpler than most parents expect:
Step 1: Order your kit before your due date. Your collection kit arrives by mail, pre-packaged with everything your delivery team needs. AlphaCord's 3-in-1 kit covers cord blood, cord tissue, and placental tissue — all from a single collection.
Step 2: Inform your hospital. Let your OB or midwife know you're banking cord blood. The collection is performed by your delivery team immediately after birth, after the cord is clamped and cut. It is completely non-invasive and does not interfere with delayed cord clamping when pre-arranged.
Step 3: The kit is shipped to the lab. AlphaCord's temperature-protected, electronically tracked transport system ensures your sample reaches the laboratory safely — regardless of when labour happens.
Step 4: Processing and storage. Your sample is processed and cryopreserved. AlphaCord's 5-chamber storage bag allows up to five separate treatment-ready units from a single collection — maximising the therapeutic potential of what you've stored.
What Makes AlphaCord Different
Founded in 2002 by parents who believed quality cord blood banking shouldn't require a premium price, AlphaCord has spent more than two decades making this technology accessible to everyday American families. AlphaCord is AABB accredited, AATB accredited, and FDA registered — the full accreditation stack that matters when your stored cells need to be released for treatment.
The engraftment guarantee — up to $85,000 if stored cells fail to engraft — reflects the confidence AlphaCord places in its own processing and storage standards. And with plans starting from $81 per month for cord blood alone, the barrier to entry is lower than most families assume.
AlphaCord is also part of the CSG.BIO Group, a global network with 750,000+ samples stored — giving families access to the infrastructure and expertise of a world-class biobanking organisation, with the affordability of a provider built specifically for the US market.
Frequently Asked Questions
What is the difference between cord blood and cord tissue banking? Cord blood contains haematopoietic stem cells (HSCs), which form all blood and immune cells and have the most established clinical track record. Cord tissue contains mesenchymal stem cells (MSCs), which have different regenerative properties and are the subject of rapidly growing clinical research. Banking both preserves two distinct stem cell populations with complementary therapeutic potential.
Can cord blood stem cells be used by other family members? Yes. While the stored cells belong to your baby, they can potentially be used by siblings or parents if there is a sufficient HLA match. A sibling is statistically the most likely compatible match. This is one reason cord blood banking is particularly valuable for families with a history of conditions treatable by stem cell transplant.
Is cord blood banking compatible with delayed cord clamping? Yes, when pre-arranged with your delivery team. Delayed cord clamping (typically 30–60 seconds) can be accommodated before collection begins. Discuss this with your OB or midwife in advance so the team is prepared.
How long can cord blood stem cells be stored? Research and modelling suggest cord blood can remain viable for decades under proper cryopreservation conditions. Studies on samples stored for 20+ years show no significant degradation in cell viability. The science supports long-term storage with confidence.
What happens if I need to use the cells and they don't engraft? AlphaCord offers an engraftment guarantee of up to $85,000 in the event that stored cells fail to engraft when used in a qualifying transplant. Full terms are available on the AlphaCord website.
Start Protecting Your Family Today
Stem cells are collected once — at birth — and never available again. The decision to bank doesn't need to be complicated. AlphaCord makes it straightforward, affordable, and backed by more than two decades of experience.
